entertainment -WSS

entertainment

author：comprehensive 2025-08-28 06:21:07 - browse：65

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Today, we explore the future of obesity drugs and how they’re named, we chat with CRISPR pioneers about what it’s like to see the technology approved for human use, and more.

The need-to-know this morning:
• Bayer said it prematurely stopped a Phase 3 study in stroke prevention after independent monitors concluded its experimental blood-thinning medicine, called asundexian, showed inferior efficacy compared to a standard treatment. The asundexian study setback is a significant blow to Bayer’s effort to revamp its drug-development pipeline, analysts said.
• Carmot Therapeutics filed paperwork Friday for an initial public offering of undisclosed size. The Berkeley, Calif.-based company is developing drugs that target GLP-1 and GIP to treat diabetes and obesity, similar to Novo Nordisk’s Ozempic/Wegovy and Eli Lilly’s Mounjaro/Zepbound.
• Bristol Myers Squibb and 2Seventy Bio said the FDA will not complete an on-time review of its application seeking to expand the use of Abecma, their CAR-T therapy for multiple myeloma. Instead, the FDA will convene an advisory panel meeting — date to be determined — to examine survival data from an Abecma clinical trial.
• The U.K. and the pharmaceutical industry have reached a deal on a five-year plan outlining how the health system pays for drugs, as the country tries to keep a lid on its medicines spending while simultaneously building up its life sciences industry. STAT’s Andrew Joseph has more here.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections
Next article： Study fuels hope CAR

hotspot

focus

WSS

Virtual repurposing can help discover new uses for existing drugs

Readout LOUD podcast: What to know about H5N1 bird flu

CDC panel: People 65 and older should get a Covid spring booster shot

Apple Watch's A

Medicare isn't yet testing food as medicine

CDC wastewater surveillance dashboard to track bird flu hotspots

hotspot

entertainment

knowledge

Medicare proposal to cover medical devices draws a mixed reaction

Elisabeth Bik tackles the widespread issue of research misconduct

Medicare proposal to cover medical devices draws a mixed reaction

Using force crossed my mind when examining a defiant young patient

Heart attack and stroke risk calculators need revising

Are embryos people? Reproductive medicine's future depends on the answer

Hepatitis C has a cure — but many Americans still lack access to it

Use wet bulb globe temperature, not heat index, to protect workers

Moonlake's readout produced a cash windfall. Risks remain

Use wet bulb globe temperature, not heat index, to protect workers

knowledge

Laying a path for careers in science

Software glitch causes Tandem insulin pump to shutdown, FDA warns

Readout Newsletter: Beam, Prozac, "TechBio" and more

Study: Adult vaccinations pay for themselves in societal benefits

Telehealth startups turn to complex chronic diseases

Pfizer is about to make a big push in cancer. Will investors listen?

hotspot

leisure time

focus

knowledge